Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice Regarding Completion of Acquisition of Treasury Shares
Partnership and License Agreement for the Commercialization of Sebetralstat for Hereditary Angioedema in Japan
KAKEN PHARMA, Last Fiscal Year Ordinary Profit Revised Downward by 1%
Revision to Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2025
Partial Revision of Long-Term Business Plan 2031
Notice Regarding Acquisition of Treasury Shares
KAKEN PHARMA, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 2.8 times, Exceeds Full-Year Plan
[Summary]Consolidated Financial Results for the Nine-Months Period of Fiscal 2024 (Nine-Month Period Ended December 31, 2024) [JGAAP]
KAKEN PHARMACEUTICAL CO.,LTD., First Half Ordinary Profit Increases by 3.5 times, July-September Ordinary Profit Increases by 7.5 times
[Summary]Consolidated Financial Results for the Six-Months Period of Fiscal 2024 (Six-Month Period Ended September 30, 2024) [JGAAP]